New oncogenic drivers in NSCLC

The potential of KRAS inhibitors for non-small-cell lung cancer

Managing Hodgkin lymphoma during the COVID-19 outbreak

Updates from ECCO: The European Cancer Strategy and COVID-19

CARTs for the treatment of T-cell malignancies

COVID-19: The management of coronavirus patients with cancer, examples from Italy

Testing and treatment for CDH1 in hereditary diffuse gastric cancer and breast cancer

Systematic therapy of driver mutated NSCLC

Shorter hormone therapy for prostate cancer

PRIAS: Active surveillance for men with low risk prostate cancer

The changing landscape of cancer in India

NIVOREN: Nivolumab in a 'real world setting' for metastatic clear-cell renal cell carcinoma